Chart 1 In late April, we revisited our Infrastructure Basket in light of President Biden pumping out one fiscal package after another. BCA’s view also remains that the populist shift in US politics is just getting…
Highlights Global stocks are very vulnerable to a correction. But cyclically the Fed is committed to an inflation overshoot and the global economy is recovering. China’s fiscal-and-credit impulse fell sharply, which leaves global…
Overweight In last week’s Strategy Report, we made a couple of changes within the health care universe; namely we upgraded pharma to neutral and boosted biotech stocks to overweight both of which lifted the S&P…
Chart 1 Fourteen months ago we penned a report titled “20 Reasons To Buy Equities” and now that the SPX is up 2,000 points since that trough, the risk/reward tradeoff is to the downside and we are compelled to book…
Feature Chinese stocks remain in limbo despite robust economic data in April and early May (Chart 1). Onshore equities are pricing in policy tightening risks and a peak in the domestic economic cycle. Meanwhile, a regulatory…
Dear client, Next Monday May 17, instead of sending you a Strategy Report we will be hosting our quarterly webcast “From Alpha To Omega With Anastasios” at 10am EST with two special guests, addressing the recent market…
This Monday we closed both our cyclical and high-conviction S&P pharmaceuticals underweights for a combined gain of 23%, since inception. We did not wish to overstay our welcome in this defensive industry as not only is…
Highlights US natural gas prices will remain well supported over the April-October injection season, as the global economic expansion gains traction, particularly in Europe, which also is refilling depleted storage levels. China's…